Literature DB >> 22174258

SSLPred: predicting synthetic sickness lethality.

Nirmalya Bandyopadhyay1, Sanjay Ranka, Tamer Kahveci.   

Abstract

Two genes in an organism have a Synthetic Sickness Lethality (SSL) interaction, if their joint deletion leads to a lower than expected fitness. Synthetic Gene Array (SGA) is a technique that helps in identifying SSL values for pairs of genes in a given set of genes. SSL interactions are useful to discover the co-expressed gene groups in the regulatory and signaling networks. Also, they are used to unravel the pair of pathways (subset of physically interacting genes) that substitute the functions of each other. Generating an SGA entry is costly as it requires producing and monitoring a double mutant (a progeny with two mutated genes). Generating a comprehensive SGA can be very expensive as the number of gene pairs is quadratic in the number of genes of the corresponding organism. In this paper, we develop a new method SSLPred to predict the SSL interactions in an organism. Our method is built on the concept of Between Pathway Models (BPM), where majority of the SSL pairs span across the two functionally complementing pathways. We develop a regression based approach that learns the mapping between the gene expressions of single deletion mutant to the corresponding SGA entries. We compare our method to the one by Hescott et al. for predicting the GI (Genetic Interaction) score of Saccharomyces cerevisiae (S. cerevisiae) on four benchmark datasets. On different experimental setups, on average SSLPred performs significantly better compared to the other method.

Entities:  

Mesh:

Year:  2012        PMID: 22174258

Source DB:  PubMed          Journal:  Pac Symp Biocomput        ISSN: 2335-6928


  2 in total

1.  Identifying proteins controlling key disease signaling pathways.

Authors:  Anthony Gitter; Ziv Bar-Joseph
Journal:  Bioinformatics       Date:  2013-07-01       Impact factor: 6.937

2.  High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H.

Authors:  Hiroo Imai; Shunsuke Kato; Yasuhiro Sakamoto; Yuichi Kakudo; Hideki Shimodaira; Chikashi Ishioka
Journal:  Oncol Rep       Date:  2013-12-30       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.